Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Above 50-Day Moving Average – What’s Next?

Theravance Biopharma, Inc. (NASDAQ:TBPH)’s share price passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $9.30 and traded as high as $9.44. Theravance Biopharma shares last traded at $9.35, with a volume of 167,372 shares changing hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a report on Tuesday, February 25th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Theravance Biopharma has an average rating of “Hold” and an average price target of $13.75.

Theravance Biopharma Stock Up 1.3 %

The business’s fifty day moving average price is $9.30 and its 200 day moving average price is $9.03. The firm has a market capitalization of $462.55 million, a PE ratio of -9.26 and a beta of 0.15.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The company had revenue of $18.75 million for the quarter, compared to analyst estimates of $29.90 million. On average, analysts anticipate that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now owns 309,565 shares of the company’s stock, valued at $2,786,085. This represents a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Several institutional investors and hedge funds have recently modified their holdings of the business. Aquatic Capital Management LLC purchased a new position in shares of Theravance Biopharma during the fourth quarter valued at approximately $25,000. Quantbot Technologies LP purchased a new position in shares of Theravance Biopharma during the third quarter valued at approximately $60,000. KLP Kapitalforvaltning AS purchased a new position in shares of Theravance Biopharma during the fourth quarter valued at approximately $69,000. Teacher Retirement System of Texas purchased a new position in shares of Theravance Biopharma during the fourth quarter valued at approximately $103,000. Finally, ClearAlpha Technologies LP purchased a new position in shares of Theravance Biopharma during the fourth quarter valued at approximately $109,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.